Share Price and Basic Stock Data
Last Updated: February 9, 2026, 10:14 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dolphin Medical Services Ltd operates within the Hospitals & Medical Services sector, with a current market capitalization of ₹5.01 Cr and a share price of ₹3.32. The company reported sales of ₹0.61 Cr for the fiscal year ending March 2023, which is a modest increase from ₹0.52 Cr in the previous fiscal year. Over recent quarters, Dolphin’s sales have fluctuated, peaking at ₹0.22 Cr in December 2022 and dipping to ₹0.08 Cr in March 2023. The latest quarterly sales for September 2023 stood at ₹0.18 Cr, indicating a gradual recovery. The trailing twelve months (TTM) revenue is reported at ₹0.73 Cr. Despite this upward trend, the overall revenue remains low compared to industry standards, suggesting significant room for growth. The company’s operational performance has been characterized by a lack of scale, which is critical in the healthcare sector. The fluctuating revenue stream highlights the challenges faced in achieving consistent growth in a competitive environment.
Profitability and Efficiency Metrics
Dolphin Medical Services Ltd has faced profitability challenges, with a net profit of ₹-0.02 Cr reported for the year ending March 2023. The operating profit margin (OPM) was recorded at 11.11%, but this figure masks a troubling trend as the company has frequently reported negative operating profits in previous periods. For example, in March 2023, the operating profit stood at ₹-0.08 Cr, while in the fiscal year ending March 2024, it is projected to remain flat at ₹-0.08 Cr. The interest coverage ratio (ICR) is relatively strong at 5.76x, indicating that the company can cover its interest expenses comfortably, but the overall financial performance remains weak. The return on equity (ROE) is reported at 30%, while the return on capital employed (ROCE) is lower at 18%, suggesting that while equity returns are satisfactory, capital efficiency needs improvement. The cash conversion cycle (CCC) of 30.42 days reflects a reasonable operational efficiency but indicates potential delays in cash flow that could impact liquidity.
Balance Sheet Strength and Financial Ratios
Dolphin Medical Services Ltd’s balance sheet reveals a concerning picture with total borrowings of ₹0.83 Cr against reserves of ₹-5.02 Cr. This negative reserve position indicates accumulated losses over the years, which pose a risk to financial stability. The price-to-book value ratio (P/BV) is notably low at 0.13x, suggesting that the market values the company significantly lower than its book value, which may deter potential investors. The company’s total assets are recorded at ₹12.08 Cr, with fixed assets declining to ₹2.76 Cr, indicating a reduction in physical assets that could hinder operational capacity. The current ratio is exceptionally high at 29.59, which suggests strong liquidity; however, this could also imply inefficient asset utilization. Overall, the balance sheet reflects a company struggling with profitability while maintaining a relatively strong liquidity position.
Shareholding Pattern and Investor Confidence
The shareholding structure of Dolphin Medical Services Ltd shows that promoters hold 26.44% of the company, while the public holds a significant 73.57%. The number of shareholders has fluctuated slightly, with 9,349 reported as of March 2025. This distribution indicates a relatively high public interest in the company, which may reflect investor confidence despite the financial struggles. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) suggests a lack of institutional backing, which could be a deterrent for larger investors. The stability of promoter holdings indicates a commitment to the company, but the overall low market capitalization and ongoing losses may raise concerns about future prospects. The high public shareholding could lead to volatility if sentiment shifts, especially given the company’s weak financial performance.
Outlook, Risks, and Final Insight
The outlook for Dolphin Medical Services Ltd remains challenging due to ongoing profitability issues and a negative reserve position. The company’s ability to improve operational efficiency and generate consistent revenue growth is critical for future sustainability. Key risks include reliance on a limited revenue base and potential liquidity constraints despite a high current ratio. Additionally, the lack of institutional investor support poses a significant challenge for raising future capital. However, the high ROE indicates that the company can generate returns on equity effectively, provided it can stabilize its operations. If Dolphin Medical can successfully implement strategies to enhance its service offerings and improve operational efficiencies, there may be a pathway to recovery. Conversely, continued losses could lead to further erosion of shareholder value, necessitating urgent strategic realignment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.2 Cr. | 144 | 187/120 | 117 | 2.43 % | 23.6 % | 20.7 % | 10.0 | |
| Global Longlife Hospital and Research Ltd | 13.5 Cr. | 12.8 | 33.0/12.8 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.2 Cr. | 9.89 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 105 Cr. | 55.8 | 98.7/52.2 | 23.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.3 Cr. | 3.58 | 6.12/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,758.00 Cr | 691.23 | 95.15 | 92.86 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.16 | 0.22 | 0.08 | 0.15 | 0.18 | 0.20 | 0.14 | 0.14 | 0.25 | 0.24 | 0.14 | 0.17 | 0.18 |
| Expenses | 0.17 | 0.20 | 0.16 | 0.13 | 0.17 | 0.20 | 0.27 | 0.13 | 0.23 | 0.23 | 0.19 | 0.14 | 0.16 |
| Operating Profit | -0.01 | 0.02 | -0.08 | 0.02 | 0.01 | 0.00 | -0.13 | 0.01 | 0.02 | 0.01 | -0.05 | 0.03 | 0.02 |
| OPM % | -6.25% | 9.09% | -100.00% | 13.33% | 5.56% | 0.00% | -92.86% | 7.14% | 8.00% | 4.17% | -35.71% | 17.65% | 11.11% |
| Other Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 | 0.03 |
| Profit before tax | -0.02 | 0.01 | -0.09 | 0.02 | 0.01 | 0.00 | -0.13 | 0.01 | 0.02 | 0.01 | -0.07 | 0.03 | 0.00 |
| Tax % | 0.00% | 0.00% | 11.11% | 0.00% | 0.00% | 7.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.01 | 0.01 | -0.10 | 0.01 | 0.01 | 0.00 | -0.13 | 0.01 | 0.02 | 0.01 | -0.07 | 0.03 | 0.01 |
| EPS in Rs | -0.01 | 0.01 | -0.07 | 0.01 | 0.01 | 0.00 | -0.09 | 0.01 | 0.01 | 0.01 | -0.05 | 0.02 | 0.01 |
Last Updated: December 27, 2025, 5:36 am
Below is a detailed analysis of the quarterly data for Dolphin Medical Services Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.17 Cr. (Jun 2025) to 0.18 Cr., marking an increase of 0.01 Cr..
- For Expenses, as of Sep 2025, the value is 0.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.14 Cr. (Jun 2025) to 0.16 Cr., marking an increase of 0.02 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.02 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Jun 2025) to 0.02 Cr., marking a decrease of 0.01 Cr..
- For OPM %, as of Sep 2025, the value is 11.11%. The value appears to be declining and may need further review. It has decreased from 17.65% (Jun 2025) to 11.11%, marking a decrease of 6.54%.
- For Other Income, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.01 Cr. (Jun 2025) to 0.03 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Jun 2025) to 0.00 Cr., marking a decrease of 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.03 Cr. (Jun 2025) to 0.01 Cr., marking a decrease of 0.02 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 0.02 (Jun 2025) to 0.01, marking a decrease of 0.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:50 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.96 | 0.36 | 0.57 | 0.35 | 0.15 | 0.06 | 0.18 | 0.47 | 0.52 | 0.61 | 0.68 | 0.78 | 0.73 |
| Expenses | 1.06 | 0.39 | 0.39 | 0.33 | 0.23 | 0.20 | 0.52 | 6.24 | 0.66 | 0.69 | 0.76 | 0.78 | 0.72 |
| Operating Profit | -0.10 | -0.03 | 0.18 | 0.02 | -0.08 | -0.14 | -0.34 | -5.77 | -0.14 | -0.08 | -0.08 | 0.00 | 0.01 |
| OPM % | -10.42% | -8.33% | 31.58% | 5.71% | -53.33% | -233.33% | -188.89% | -1,227.66% | -26.92% | -13.11% | -11.76% | 0.00% | 1.37% |
| Other Income | 0.00 | 0.01 | 0.15 | 0.02 | 0.09 | -0.63 | 0.05 | 5.55 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.05 | 0.05 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Depreciation | 0.71 | 0.52 | 0.34 | 0.33 | 0.33 | 0.24 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.08 |
| Profit before tax | -0.86 | -0.59 | -0.07 | -0.30 | -0.33 | -1.02 | -0.36 | -0.29 | -0.17 | -0.11 | -0.10 | -0.03 | -0.03 |
| Tax % | 0.00% | -3.39% | -28.57% | -10.00% | -12.12% | -1.96% | 5.56% | 6.90% | 5.88% | 9.09% | 10.00% | 0.00% | |
| Net Profit | -0.86 | -0.57 | -0.05 | -0.27 | -0.30 | -1.01 | -0.39 | -0.31 | -0.19 | -0.12 | -0.10 | -0.03 | -0.02 |
| EPS in Rs | -0.57 | -0.38 | -0.03 | -0.18 | -0.20 | -0.67 | -0.26 | -0.21 | -0.13 | -0.08 | -0.07 | -0.02 | -0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 33.72% | 91.23% | -440.00% | -11.11% | -236.67% | 61.39% | 20.51% | 38.71% | 36.84% | 16.67% | 70.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 57.51% | -531.23% | 428.89% | -225.56% | 298.05% | -40.87% | 18.20% | -1.87% | -20.18% | 53.33% |
Dolphin Medical Services Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 34% |
| 3 Years: | 14% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 23% |
| TTM: | 91% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 6% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | -1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 |
| Reserves | -1.72 | -2.30 | -2.34 | -2.61 | -2.91 | -3.91 | -4.30 | -4.61 | -4.80 | -4.92 | -5.03 | -5.06 | -5.02 |
| Borrowings | 8.10 | 8.05 | 8.16 | 8.21 | 8.21 | 6.22 | 6.37 | 0.61 | 0.68 | 0.76 | 0.80 | 0.87 | 0.83 |
| Other Liabilities | 0.75 | 0.74 | 0.67 | 0.65 | 0.61 | 0.58 | 0.71 | 1.23 | 1.26 | 1.23 | 1.27 | 1.17 | 1.30 |
| Total Liabilities | 22.23 | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.21 |
| Fixed Assets | 11.23 | 14.50 | 10.36 | 10.03 | 9.70 | 6.79 | 6.74 | 3.00 | 2.94 | 2.87 | 2.83 | 2.76 | 6.67 |
| CWIP | 5.93 | 2.14 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 0.31 |
| Investments | 0.52 | 0.52 | 0.52 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
| Other Assets | 4.55 | 4.43 | 4.78 | 4.98 | 4.97 | 4.86 | 4.80 | 4.83 | 4.80 | 4.80 | 4.81 | 4.82 | 4.82 |
| Total Assets | 22.23 | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.21 |
Below is a detailed analysis of the balance sheet data for Dolphin Medical Services Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 15.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.10 Cr..
- For Reserves, as of Sep 2025, the value is -5.02 Cr.. The value appears to be improving (becoming less negative). It has improved from -5.06 Cr. (Mar 2025) to -5.02 Cr., marking an improvement of 0.04 Cr..
- For Borrowings, as of Sep 2025, the value is 0.83 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 0.87 Cr. (Mar 2025) to 0.83 Cr., marking a decrease of 0.04 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.17 Cr. (Mar 2025) to 1.30 Cr., marking an increase of 0.13 Cr..
- For Total Liabilities, as of Sep 2025, the value is 12.21 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.08 Cr. (Mar 2025) to 12.21 Cr., marking an increase of 0.13 Cr..
- For Fixed Assets, as of Sep 2025, the value is 6.67 Cr.. The value appears strong and on an upward trend. It has increased from 2.76 Cr. (Mar 2025) to 6.67 Cr., marking an increase of 3.91 Cr..
- For CWIP, as of Sep 2025, the value is 0.31 Cr.. The value appears to be declining and may need further review. It has decreased from 4.09 Cr. (Mar 2025) to 0.31 Cr., marking a decrease of 3.78 Cr..
- For Investments, as of Sep 2025, the value is 0.41 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.41 Cr..
- For Other Assets, as of Sep 2025, the value is 4.82 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.82 Cr..
- For Total Assets, as of Sep 2025, the value is 12.21 Cr.. The value appears strong and on an upward trend. It has increased from 12.08 Cr. (Mar 2025) to 12.21 Cr., marking an increase of 0.13 Cr..
However, the Borrowings (0.83 Cr.) are higher than the Reserves (-5.02 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -8.20 | -8.08 | -7.98 | -8.19 | -8.29 | -6.36 | -6.71 | -6.38 | -0.82 | -0.84 | -0.88 | -0.87 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | 36.50 | 36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 |
| Days Payable | 12.17 | 73.00 | 0.00 | 0.00 | 0.00 | |||||||
| Cash Conversion Cycle | 24.33 | -36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 |
| Working Capital Days | 589.32 | 1,449.86 | 1,171.84 | 2,106.57 | 4,891.00 | 11,619.17 | 3,629.72 | 986.28 | 898.46 | 771.89 | 687.06 | 645.77 |
| ROCE % | -3.69% | -2.55% | -0.05% | -0.96% | -1.56% | -1.69% | -2.02% | -1.98% | -1.45% | -0.91% | -0.83% | -0.18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.99 |
| Diluted EPS (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.99 |
| Cash EPS (Rs.) | 0.19 | -0.03 | -0.09 | -0.88 | -0.55 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 8.50 | 8.53 | 8.91 | 9.47 | 10.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 8.50 | 8.53 | 8.91 | 9.47 | 10.78 |
| Revenue From Operations / Share (Rs.) | 0.37 | 0.24 | 0.63 | 0.75 | 2.49 |
| PBDIT / Share (Rs.) | 0.21 | -0.02 | -0.06 | -0.39 | 0.25 |
| PBIT / Share (Rs.) | -0.01 | -0.36 | -0.53 | -0.82 | -0.17 |
| PBT / Share (Rs.) | -0.04 | -0.39 | -0.57 | -1.29 | -0.95 |
| Net Profit / Share (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.98 |
| NP After MI And SOA / Share (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.98 |
| PBDIT Margin (%) | 56.85 | -9.66 | -10.55 | -52.32 | 10.07 |
| PBIT Margin (%) | -2.35 | -146.84 | -85.02 | -108.98 | -7.09 |
| PBT Margin (%) | -12.23 | -156.99 | -89.80 | -170.48 | -38.47 |
| Net Profit Margin (%) | -8.16 | -152.48 | -90.22 | -173.28 | -39.61 |
| NP After MI And SOA Margin (%) | -8.16 | -152.48 | -90.22 | -173.28 | -39.61 |
| Return on Networth / Equity (%) | -0.36 | -4.48 | -6.46 | -13.88 | -9.18 |
| Return on Capital Employeed (%) | -0.06 | -2.56 | -3.67 | -5.36 | -1.08 |
| Return On Assets (%) | -0.21 | -2.65 | -3.87 | -8.49 | -6.03 |
| Long Term Debt / Equity (X) | 0.63 | 0.62 | 0.60 | 0.57 | 0.47 |
| Total Debt / Equity (X) | 0.63 | 0.62 | 0.60 | 0.57 | 0.47 |
| Asset Turnover Ratio (%) | 0.02 | 0.01 | 0.04 | 0.04 | 0.14 |
| Current Ratio (X) | 29.59 | 15.97 | 17.40 | 17.36 | 17.80 |
| Quick Ratio (X) | 29.46 | 15.89 | 17.10 | 17.01 | 17.49 |
| Interest Coverage Ratio (X) | 5.76 | -0.95 | -2.21 | -0.85 | 0.32 |
| Interest Coverage Ratio (Post Tax) (X) | 0.17 | -14.03 | -17.86 | -1.82 | -0.26 |
| Enterprise Value (Cr.) | 10.00 | 10.11 | 9.76 | 9.95 | 10.69 |
| EV / Net Operating Revenue (X) | 17.63 | 26.84 | 10.18 | 8.72 | 2.84 |
| EV / EBITDA (X) | 31.01 | -277.52 | -96.45 | -16.66 | 28.21 |
| MarketCap / Net Operating Revenue (X) | 3.12 | 5.29 | 1.67 | 1.46 | 0.78 |
| Price / BV (X) | 0.13 | 0.15 | 0.11 | 0.11 | 0.18 |
| Price / Net Operating Revenue (X) | 3.12 | 5.30 | 1.67 | 1.46 | 0.78 |
| EarningsYield | -0.02 | -0.28 | -0.53 | -1.19 | -0.50 |
After reviewing the key financial ratios for Dolphin Medical Services Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 15) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For Diluted EPS (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For Cash EPS (Rs.), as of Mar 16, the value is 0.19. This value is below the healthy minimum of 3. It has increased from -0.03 (Mar 15) to 0.19, marking an increase of 0.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 8.50. It has decreased from 8.53 (Mar 15) to 8.50, marking a decrease of 0.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 8.50. It has decreased from 8.53 (Mar 15) to 8.50, marking a decrease of 0.03.
- For Revenue From Operations / Share (Rs.), as of Mar 16, the value is 0.37. It has increased from 0.24 (Mar 15) to 0.37, marking an increase of 0.13.
- For PBDIT / Share (Rs.), as of Mar 16, the value is 0.21. This value is below the healthy minimum of 2. It has increased from -0.02 (Mar 15) to 0.21, marking an increase of 0.23.
- For PBIT / Share (Rs.), as of Mar 16, the value is -0.01. This value is below the healthy minimum of 0. It has increased from -0.36 (Mar 15) to -0.01, marking an increase of 0.35.
- For PBT / Share (Rs.), as of Mar 16, the value is -0.04. This value is below the healthy minimum of 0. It has increased from -0.39 (Mar 15) to -0.04, marking an increase of 0.35.
- For Net Profit / Share (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 2. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 2. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For PBDIT Margin (%), as of Mar 16, the value is 56.85. This value is within the healthy range. It has increased from -9.66 (Mar 15) to 56.85, marking an increase of 66.51.
- For PBIT Margin (%), as of Mar 16, the value is -2.35. This value is below the healthy minimum of 10. It has increased from -146.84 (Mar 15) to -2.35, marking an increase of 144.49.
- For PBT Margin (%), as of Mar 16, the value is -12.23. This value is below the healthy minimum of 10. It has increased from -156.99 (Mar 15) to -12.23, marking an increase of 144.76.
- For Net Profit Margin (%), as of Mar 16, the value is -8.16. This value is below the healthy minimum of 5. It has increased from -152.48 (Mar 15) to -8.16, marking an increase of 144.32.
- For NP After MI And SOA Margin (%), as of Mar 16, the value is -8.16. This value is below the healthy minimum of 8. It has increased from -152.48 (Mar 15) to -8.16, marking an increase of 144.32.
- For Return on Networth / Equity (%), as of Mar 16, the value is -0.36. This value is below the healthy minimum of 15. It has increased from -4.48 (Mar 15) to -0.36, marking an increase of 4.12.
- For Return on Capital Employeed (%), as of Mar 16, the value is -0.06. This value is below the healthy minimum of 10. It has increased from -2.56 (Mar 15) to -0.06, marking an increase of 2.50.
- For Return On Assets (%), as of Mar 16, the value is -0.21. This value is below the healthy minimum of 5. It has increased from -2.65 (Mar 15) to -0.21, marking an increase of 2.44.
- For Long Term Debt / Equity (X), as of Mar 16, the value is 0.63. This value is within the healthy range. It has increased from 0.62 (Mar 15) to 0.63, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 16, the value is 0.63. This value is within the healthy range. It has increased from 0.62 (Mar 15) to 0.63, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 16, the value is 0.02. It has increased from 0.01 (Mar 15) to 0.02, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 16, the value is 29.59. This value exceeds the healthy maximum of 3. It has increased from 15.97 (Mar 15) to 29.59, marking an increase of 13.62.
- For Quick Ratio (X), as of Mar 16, the value is 29.46. This value exceeds the healthy maximum of 2. It has increased from 15.89 (Mar 15) to 29.46, marking an increase of 13.57.
- For Interest Coverage Ratio (X), as of Mar 16, the value is 5.76. This value is within the healthy range. It has increased from -0.95 (Mar 15) to 5.76, marking an increase of 6.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 16, the value is 0.17. This value is below the healthy minimum of 3. It has increased from -14.03 (Mar 15) to 0.17, marking an increase of 14.20.
- For Enterprise Value (Cr.), as of Mar 16, the value is 10.00. It has decreased from 10.11 (Mar 15) to 10.00, marking a decrease of 0.11.
- For EV / Net Operating Revenue (X), as of Mar 16, the value is 17.63. This value exceeds the healthy maximum of 3. It has decreased from 26.84 (Mar 15) to 17.63, marking a decrease of 9.21.
- For EV / EBITDA (X), as of Mar 16, the value is 31.01. This value exceeds the healthy maximum of 15. It has increased from -277.52 (Mar 15) to 31.01, marking an increase of 308.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 16, the value is 3.12. This value exceeds the healthy maximum of 3. It has decreased from 5.29 (Mar 15) to 3.12, marking a decrease of 2.17.
- For Price / BV (X), as of Mar 16, the value is 0.13. This value is below the healthy minimum of 1. It has decreased from 0.15 (Mar 15) to 0.13, marking a decrease of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 16, the value is 3.12. This value exceeds the healthy maximum of 3. It has decreased from 5.30 (Mar 15) to 3.12, marking a decrease of 2.18.
- For EarningsYield, as of Mar 16, the value is -0.02. This value is below the healthy minimum of 5. It has increased from -0.28 (Mar 15) to -0.02, marking an increase of 0.26.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dolphin Medical Services Ltd:
- Net Profit Margin: -8.16%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.06% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.36% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 29.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 95.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.63
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -8.16%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | No.417, Sanali Heavens, Ameerpet, Hyderabad Telangana 500073 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. G V Mohan Prasad | Managing Director & CEO |
| Dr. M Lakshmi Sudha | WholeTime Director & CFO |
| Mr. Nanapaneni Buddha Sagar | Director |
| Mr. Narendra Seena Karkera | Independent Director |
| Mr. Vinay Vishnuraj Nayak | Independent Director |
FAQ
What is the intrinsic value of Dolphin Medical Services Ltd?
Dolphin Medical Services Ltd's intrinsic value (as of 11 February 2026) is ₹0.26 which is 92.53% lower the current market price of ₹3.48, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹5.25 Cr. market cap, FY2025-2026 high/low of ₹3.48/1.98, reserves of ₹-5.02 Cr, and liabilities of ₹12.21 Cr.
What is the Market Cap of Dolphin Medical Services Ltd?
The Market Cap of Dolphin Medical Services Ltd is 5.25 Cr..
What is the current Stock Price of Dolphin Medical Services Ltd as on 11 February 2026?
The current stock price of Dolphin Medical Services Ltd as on 11 February 2026 is ₹3.48.
What is the High / Low of Dolphin Medical Services Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dolphin Medical Services Ltd stocks is ₹3.48/1.98.
What is the Stock P/E of Dolphin Medical Services Ltd?
The Stock P/E of Dolphin Medical Services Ltd is .
What is the Book Value of Dolphin Medical Services Ltd?
The Book Value of Dolphin Medical Services Ltd is 6.68.
What is the Dividend Yield of Dolphin Medical Services Ltd?
The Dividend Yield of Dolphin Medical Services Ltd is 0.00 %.
What is the ROCE of Dolphin Medical Services Ltd?
The ROCE of Dolphin Medical Services Ltd is 0.18 %.
What is the ROE of Dolphin Medical Services Ltd?
The ROE of Dolphin Medical Services Ltd is 0.30 %.
What is the Face Value of Dolphin Medical Services Ltd?
The Face Value of Dolphin Medical Services Ltd is 10.0.